189 related articles for article (PubMed ID: 32383192)
1. Rare lymphomas in routine practice-Treatment and outcome in Waldenström's macroglobulinaemia in the prospective German Tumour Registry Lymphatic Neoplasms.
Knauf W; Abenhardt W; Slawik HR; Bückner U; Otremba B; Sauer A; Zahn MO; Wetzel N; Kaiser-Osterhues A; Houet L; Marschner N;
Hematol Oncol; 2020 Aug; 38(3):344-352. PubMed ID: 32383192
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT; Shustik C; García-Sanz R; Cornell RF; de Larrea CF; Castillo JJ; Granell M; Kyrtsonis MC; Leblond V; Symeonidis A; Kastritis E; Singh P; Li J; Graef T; Bilotti E; Treon S; Buske C;
Lancet Oncol; 2017 Feb; 18(2):241-250. PubMed ID: 27956157
[TBL] [Abstract][Full Text] [Related]
3. Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
Knauf W; Abenhardt W; Koenigsmann M; Maintz C; Sandner R; Zahn MO; Schnell R; Tech S; Kaiser-Osterhues A; Houet L; Marschner N;
Hematol Oncol; 2021 Aug; 39(3):313-325. PubMed ID: 33942348
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).
Laribi K; Poulain S; Willems L; Merabet F; Herbaux C; Roos-Weil D; Laribi de Materre I; Roussel X; Nudel M; Tricot S; Dupuis J; Le Calloch R; Bareau B; Leblond V
Br J Haematol; 2024 Jun; 204(6):2233-2236. PubMed ID: 38504454
[TBL] [Abstract][Full Text] [Related]
5. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia.
Treon SP; Hunter Z; Barnagan AR
Clin Lymphoma; 2005 Mar; 5(4):273-7. PubMed ID: 15794864
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
Buske C; Tedeschi A; Trotman J; García-Sanz R; MacDonald D; Leblond V; Mahe B; Herbaux C; Matous JV; Tam CS; Heffner LT; Varettoni M; Palomba ML; Shustik C; Kastritis E; Treon SP; Ping J; Hauns B; Arango-Hisijara I; Dimopoulos MA
J Clin Oncol; 2022 Jan; 40(1):52-62. PubMed ID: 34606378
[TBL] [Abstract][Full Text] [Related]
7. Outcome of stem cell transplantation for Waldenström's macroglobulinemia: analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group.
Sakurai M; Mori T; Uchiyama H; Ago H; Iwato K; Eto T; Iwasaki H; Kawata T; Takamatsu H; Yamasaki S; Takanashi M; Ichinohe T; Atsuta Y; Suzuki R
Ann Hematol; 2020 Jul; 99(7):1635-1642. PubMed ID: 32424672
[TBL] [Abstract][Full Text] [Related]
8. Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia.
Herth I; Hensel M; Rieger M; Horstmann K; Hiddemann W; Dreyling M; Koniczek S; Witzens-Harig M; Ho AD
Leuk Lymphoma; 2015 Jan; 56(1):97-102. PubMed ID: 24724778
[TBL] [Abstract][Full Text] [Related]
9. Alkylating Agents in the Treatment of Waldenström Macroglobulinemia.
Buske C
Hematol Oncol Clin North Am; 2018 Oct; 32(5):821-827. PubMed ID: 30190020
[TBL] [Abstract][Full Text] [Related]
10. Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma-data from the prospective German Tumour Registry Lymphatic Neoplasms.
Knauf W; Abenhardt W; Mohm J; Rauh J; Harde J; Kaiser-Osterhues A; Jänicke M; Marschner N;
Eur J Haematol; 2019 Nov; 103(5):460-471. PubMed ID: 31314918
[TBL] [Abstract][Full Text] [Related]
11. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
[TBL] [Abstract][Full Text] [Related]
12. Update in indolent non-Hodgkin lymphoma (NHL): paradigm for Waldenström's macroglobulinemia (WM).
Chiappella A; Ciochetto C; Orsucci L; Vitolo U
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):149-51. PubMed ID: 21454219
[TBL] [Abstract][Full Text] [Related]
13. Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
Durot E; Tomowiak C; Michallet AS; Dupuis J; Hivert B; Leprêtre S; Toussaint E; Godet S; Merabet F; Van Den Neste E; Ivanoff S; Roussel X; Zini JM; Regny C; Lemal R; Sutton L; Perrot A; Le Dû K; Kanagaratnam L; Morel P; Leblond V; Delmer A
Br J Haematol; 2017 Nov; 179(3):439-448. PubMed ID: 28770576
[TBL] [Abstract][Full Text] [Related]
14. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia.
Castillo JJ; Gustine JN; Meid K; Dubeau TE; Severns P; Xu L; Yang G; Hunter ZR; Treon SP
Br J Haematol; 2018 Apr; 181(1):77-85. PubMed ID: 29468652
[TBL] [Abstract][Full Text] [Related]
15. Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.
Buske C; Sadullah S; Kastritis E; Tedeschi A; García-Sanz R; Bolkun L; Leleu X; Willenbacher W; Hájek R; Minnema MC; Cheng M; Bilotti E; Graef T; Dimopoulos MA;
Lancet Haematol; 2018 Jul; 5(7):e299-e309. PubMed ID: 29958569
[TBL] [Abstract][Full Text] [Related]
16. Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia.
Dimopoulos MA; Hamilos G; Zervas K; Symeonidis A; Kouvatseas G; Roussou P; Gika D; Karmiris T; Bourantas K; Zomas A; Mitsouli C; Xilouri I; Vervessou E; Matsis K; Anagnostopoulos N; Economopoulos T;
Ann Oncol; 2003 Aug; 14(8):1299-305. PubMed ID: 12881396
[TBL] [Abstract][Full Text] [Related]
17. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.
Ioakimidis L; Patterson CJ; Hunter ZR; Soumerai JD; Manning RJ; Turnbull B; Sheehy P; Treon SP
Clin Lymphoma Myeloma; 2009 Mar; 9(1):62-6. PubMed ID: 19362976
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.
Buske C; Dimopoulos MA; Grunenberg A; Kastritis E; Tomowiak C; Mahé B; Troussard X; Hajek R; Viardot A; Tournilhac O; Aurran T; Lepretre S; Zerazhi H; Hivert B; Leblond V; de Guibert S; Brandefors L; Garcia-Sanz R; Gomes da Silva M; Kimby E; Schmelzle B; Kaszynski D; Dreyhaupt J; Muche R; Morel P
J Clin Oncol; 2023 May; 41(14):2607-2616. PubMed ID: 36763945
[TBL] [Abstract][Full Text] [Related]
19. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia.
Souchet L; Levy V; Ouzegdouh M; Tamburini J; Delmer A; Dupuis J; Le Gouill S; Pégourié-Bandelier B; Tournilhac O; Boubaya M; Vargaftig J; Choquet S; Leblond V;
Am J Hematol; 2016 Aug; 91(8):782-6. PubMed ID: 27135784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
